New hope for rare, deadly gynecologic cancers: drug combo trial launches
NCT ID NCT03651206
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 21 times
Summary
This clinical trial is testing whether a combination of two drugs—dostarlimab (an immunotherapy) and niraparib (a PARP inhibitor)—works better than standard chemotherapy for women with a rare and aggressive type of uterine or ovarian cancer called carcinosarcoma. The study will enroll 138 women whose cancer has returned after at least one round of chemotherapy. Researchers will compare the combination therapy to niraparib alone and to standard chemo, looking at how well the tumors shrink and how long patients live.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedaliera Ordine Mauriziano Di Torino
ACTIVE_NOT_RECRUITINGTorino, 10128, Italy
-
Azienda Ospedaliera Per L'Emergenza Cannizzaro
ACTIVE_NOT_RECRUITINGCatania, 95126, Italy
-
Azienda Ospedaliero-Universitaria di Bologna IRCCS Istituto di Ricerca e di Cura a Carattere Scientifico
ACTIVE_NOT_RECRUITINGBologna, 40138, Italy
-
CHRU Jean Minjoz
ACTIVE_NOT_RECRUITINGBesançon, 25000, France
-
CHU Saint-Etienne - Pôle de Cancérologie
NOT_YET_RECRUITINGSaint-Priest-en-Jarez, 42271, France
Contact
-
CHU de BREST - Hôpital Cavale Blanche
NOT_YET_RECRUITINGBrest, 29200, France
Contact
-
CHU de Limoges - Hôpital Dupuytren
NOT_YET_RECRUITINGLimoges, 87042, France
Contact
-
Centre Eugène Marquis
RECRUITINGRennes, 35000, France
Contact
-
Centre François Baclesse
RECRUITINGCaen, 14000, France
Contact
-
Centre Georges François Leclerc
NOT_YET_RECRUITINGDijon, 21079, France
Contact
-
Centre Hospitalier Universitaire de Nîmes, Institut de Cancérologie du GARD
NOT_YET_RECRUITINGNîmes, 30900, France
Contact
-
Centre Jean Perrin
RECRUITINGClermont-Ferrand, 63000, France
Contact
-
Centre Léon Bérard
RECRUITINGLyon, 69001, France
Contact
-
Centre Oscar Lambret
RECRUITINGLille, 59000, France
Contact
-
Centre Régional de Lutte contre le cancer - Institut Bergonié
RECRUITINGBordeaux, 33000, France
Contact
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ACTIVE_NOT_RECRUITINGRoma, 00168, Italy
-
Groupe Hospitalier des Diaconesses Croix Saint-Simon
RECRUITINGParis, 75020, France
Contact
-
Hopital Milétrie - Centre Hospitalier Universitaire Poitiers
RECRUITINGPoitiers, 86000, France
Contact
Contact
-
Hospital Clinico Universitario De Valencia
ACTIVE_NOT_RECRUITINGValencia, 46010, Spain
-
Hospital Universitario 12 De Octubre
ACTIVE_NOT_RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Ramon Y Cajal
RECRUITINGMadrid, 28034, Spain
Contact
-
Hospital Virgen de la Arrixaca
ACTIVE_NOT_RECRUITINGMurcia, 30120, Spain
-
Humanitas Mirasole S.p.A.
ACTIVE_NOT_RECRUITINGMilan, 20159, Italy
-
Hôpital Privé du Confluent S.A.S.
ACTIVE_NOT_RECRUITINGNantes, 44000, France
-
Hôpitaux Universitaires de Strasbourg
RECRUITINGStrasbourg, France
Contact
-
ICANS
COMPLETEDStrasbourg, 67200, France
-
ICL - Centre Alexis Vautrin
NOT_YET_RECRUITINGVandœuvre-lès-Nancy, 54519, France
Contact
-
ICO - Centre René Gauducheau
RECRUITINGSaint-Herblain, 44800, France
Contact
-
ICO Paul Papin
RECRUITINGAngers, 49055, France
Contact
-
IRCCS Istituto Nazionale Tumori Fondazione Pascale
ACTIVE_NOT_RECRUITINGNaples, 80131, Italy
-
IUCT Oncopole - Institut Claudius Régaud
RECRUITINGToulouse, 31000, France
Contact
-
Institut Curie
RECRUITINGParis, 76016, France
Contact
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94800, France
Contact
-
Institut Paoli Calmettes
RECRUITINGMarseille, 13000, France
Contact
-
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
ACTIVE_NOT_RECRUITINGMeldola, 47014, Italy
-
Ospedale San Raffaele S.r.l.
ACTIVE_NOT_RECRUITINGMilan, 20132, Italy
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dostarlimab and niraparib (combination of an immunotherapy and a PARP inhibitor)
What this could lead to
If successful, this could offer a new, more effective treatment option for women with rare and aggressive gynecologic cancers that have returned after chemotherapy.
What could go wrong
This is an early-to-mid-stage trial with only 138 participants, so results may not apply to all patients. The combination may cause significant side effects and may not improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.